The licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to advance miR-145 inhibition as a potential therapeutic approach for PAH.
PAH is a devastating, progressive disease repelled by abnormal cellular development and blockage of small blood vessels in the lung, which further raises pulmonary arterial pressure and, ultimately, fatal right-sided heart failure.
miRagen Therapeutics president and chief executive officer William Marshall said the results generated during the firm’s collaboration suggest that microRNA-145 controls the expression of a complex biological network that is important in the development of the devastating disease
"This agreement is one part of miRagen’s core strategy to leverage our comprehensive expertise in microRNA biology and combine optimal targets and chemistries for the development of groundbreaking therapeutics," Marshall added.